XENOVIEW

Peak

xenon xe 129 hyperpolarized

Polarean Imaging

NDAINHALATIONGAS

Approved

Dec 2022

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Magnetic Resonance Contrast Activity

Pharmacologic Class:

Hyperpolarized Contrast Agent

Loss of Exclusivity

LOE Date

Dec 29, 2035

119 months away

Patent Expiry

Dec 29, 2035

Exclusivity Expiry

Dec 23, 2027

Patent Records (2)

Patent #	Expiry	Type	Use Code
10583205	Feb 20, 2035	Product	—
11052161	Dec 29, 2035	Product	—

Company

Polarean Imaging

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers